ArticleRisk management and healthcare policy2021
Trends of Esophageal Cancer Incidence and Mortality and Its Influencing Factors in China.
Article in Risk management and healthcare policy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 15 citations in OpenAlex.
- Alcohol Consumption and Age-Specific Risk of Esophageal Cancer: Prospective Cohort Study.JMIR public health and surveillance · 2026Article
- Long-term trends in disease burden of esophageal cancer in China and the forecast until 2050.BMC gastroenterology · 2026Article
- Esophageal cancer mortality in China, 2008-2021: trends, disparities, and projections.Frontiers in public health · 2026Article
- Socioeconomic disparities in site-specific cancer incidence and mortality: Golestan cohort study.BMJ public health · 2026Article
- The Burden of Esophageal Cancer and Its Correlation with Dietary, Metabolic, and Behavioral Risk Factors in 204 Countries and Territories: Results from the Global Burden of Disease Study 2021.Medicina (Kaunas, Lithuania) · 2025Article
- Esophageal cancer trends in the US from 1992 to 2019 with projections to 2044 using SEER data.Scientific reports · 2025Article
- Efficacy and safety of camrelizumab combined with chemotherapy as second-line treatment for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma.World journal of surgical oncology · 2025Observational
- FOXP4-AS1 promotes CD8Immunologic research · 2024Article
- Prediction of five-year survival among esophageal cancer patients using machine learning.Heliyon · 2023Article
- Serum VEGF levels as a predictor of recurrence in patients with advanced‑stage esophageal squamous cell carcinoma following curative esophagectomy followed by chemotherapy or concurrent radiotherapy.Molecular and clinical oncology · 2023Article
- Chemoradiotherapy with paclitaxel liposome plus cisplatin for locally advanced esophageal squamous cell carcinoma: A retrospective analysis.Cancer medicine · 2023Article
- Geographical Disparities in Esophageal Cancer Incidence and Mortality in the United States.Healthcare (Basel, Switzerland) · 2023Article
- Review
- Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China.Risk management and healthcare policy · 2023Article
- Association of Esophageal Cancer Mortality with Municipal Socioeconomic Deprivation Level in Japan, 2013-2017: An Ecological Study Using Nationwide Data.International journal of environmental research and public health · 2022Article
- Wnt signaling pathway-related gene PRICKLE1 is a prognostic biomarker for esophageal squamous cell carcinoma.Frontiers in oncology · 2022Article
- Trends in incidence and mortality of esophageal cancer in China 1990-2019: A joinpoint and age-period-cohort analysis.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo explore the esophageal cancer (EC) incidence and mortality trends and risk factors in China during 2005-2015. MATERIALS AND
methodsThe data were stratified by area (urban, rural), gender (male, female), and age groups (0 ~, 5 ~, …, 85 ~). The age-standardized incidence rate (ASIR) and mortality rate (ASMR), age-specific incidence and mortality were calculated to describe the trends, which were analyzed by Joinpoint software, negative binomial regression model, and age-period-cohort model.
resultsTrends in EC ASIR decreased markedly during 2010-2015 (APC=-6.14%, P<0.05), and the average annual percent change (AAPC) value was -8.07% (95% confidence interval (CI): -9.98~-6.12) for rural areas during 2005-2015. The ASMR was on a fast-downward trend after 2011 (APC=-6.67%, P<0.05), with AAPC values of -1.34% (95% CI: -2.56~-0.19) for males, -3.39% (95% CI: -5.65, -1.07) for females, and -9.67% (95% CI: -10.56~-8.77) for rural areas during 2005-2015. The age-specific incidence and mortality increased with age. The risk of EC for males was 3.1675 times higher than females (P<0.001), and for urban areas, it was 0.58 times larger than rural (P<0.001). The age and period effects presented an increasing trend, with a decreasing trend for the cohort effects in incidence and mortality risk. Later birth cohorts presented lower risks than previous birth cohorts.
conclusionASIR and ASMR in China are higher in males than females, and higher in rural than urban areas, which have decreased during 2005-2015, especially in rural areas. The incidence increased with age up to the peak age group of 75. Area, gender, and age were independent risk factors for EC incidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.